Market capitalization | $0.00 |
Enterprise Value | $-2.86m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | 0.08 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-30.21m |
Free Cash Flow (TTM) Free Cash Flow | $-35.65m |
Cash position | $5.41m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast ContraFect Corp.:
1 Analyst has issued a forecast ContraFect Corp.:
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.16 -0.16 |
7%
7%
|
|
EBITDA | -30 -30 |
53%
53%
|
EBIT (Operating Income) EBIT | -30 -30 |
53%
53%
|
Net Profit | -24 -24 |
60%
60%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Head office | United States |
CEO | Michael Messinger |
Founded | 2008 |
Website | www.contrafect.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.